Investor Relations

Explore information about IDEAYA's business, strategy, pipeline, and financial performance, as well as the latest updates for the investment community.

Download IDEAYA Highlights

Stock Info
NASDAQIDYA

View all stock information

Recent News
Jul 27, 2026
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative binding vs SAM-PRMT5 cooperative binding, and CYP3A4 IC50 greater than 45 micromolar with no...

Jul 17, 2026
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced three abstract presentations at the 2026 European Society of Medical Oncology (ESMO)...

Jun 26, 2026
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 25, 2026, the...

All Releases

Events
AI Panel at the 2026 Jefferies Global Healthcare Conference
Thursday, June 4, 2026
8:45am EDT

Panel discussion featuring Yujiro S. Hata, President and Chief Executive Officer, moderated by Akash Tewari, Global Head of Biopharmaceutical Research

2026 Jefferies Global Healthcare Conference
Wednesday, June 3, 2026
7:35am EDT

Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology

All Events